Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Secrets Revealed About How Disease-Causing DNA Mutations Occur
A team of Penn State scientists has shed light on the processes that lead to certain human DNA mutations that are implicated in hundreds of inherited diseases such as tuberous sclerosis and neurofibromatosis type 1. The results one day could influence the way couples who seek to have children receive genetic counseling. The team, led by Kateryna Makova, an associate professor of biology, also includes Erika Kvikstad, a graduate student in the Department of Biology, and Francesca Chiaromonte, an associate professor of statistics. Their findings will be published in the July 2009 issue of the journal Genome Research.

Does Adding Simehicone To Sodium Phosphate Bowel Preparation Benefit Colonscopy
Bowel preparation has been reported inadequate in 10%-75% of colonoscopic examinations. None of the preparations reached all the requirements of safety, acceptance to patients with negligible discomfort, and rapid cleansing. Polyethyleneglycol is considered as the gold standard for colonoscopic bowel preparation (Grade IA), and aqueous sodium phosphate was an alternative regimen to PEG solution (Grade IA). This consensus also stated that adjunctive therapy, such as bisacodyl, metoclopramide, and simethicone, was shown to improve the quality of bowel preparation. Simethicone works as an adjunct to bowel preparationwith the purpose of diminishing foam formation and improving visualization during colonoscopy. However, the benefit of simethicone in improving colonic bowel preparation, however, was not explored in previous studies.
News of the day
Therapy For Parkinson's, Other Diseases, Advanced By ORNL
By miniaturizing a device that monitors the delivery of healthy cells, researchers at Department of Energy"s Oak Ridge National Laboratory are developing a powerful instrument for physicians to use in treating patients with Parkinson"s syndrome, brain tumors and other diseases.
Diagnostics

FDA Authorizes Emergency Use Of Another Test For 2009 H1N1 Influenza Virus

The U.S. Food and Drug Administration announced it has issued an Emergency Use Authorization (EUA) for a another diagnostic test for the 2009 H1N1 influenza virus, whose spread has caused the virus to be characterized as a pandemic by the World Health Organization. The EUA for the Focus Diagnostics Influenza H1N1 (2009) Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) diagnostic test is the third diagnostic test authorized under an EUA by the FDA since the public health emergency involving the 2009 H1N1 influenza virus was declared on April 26, 2009. The EUA allows Focus Diagnostics to distribute the test to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity tests. This test is not typically utilized in a doctor"s office-it is a complex laboratory test performed in an environment that has the necessary equipment. These tests are intended for use in the detection of the 2009 H1N1 influenza virus in patients with symptoms of respiratory infection. "This authorization will contribute to the nation"s capacity for accurate testing for the 2009 H1N1 influenza virus," said Daniel G. Schultz, M.D., director of the FDA"s Center for Devices and Radiological Health. The Focus Diagnostics test amplifies the viral genetic material obtained from swabs of the nose or throat, or from nasal discharges. A positive result indicates that the patient is infected with the 2009 H1N1 influenza virus. However, the test does not indicate the stage of infection. A negative result does not preclude influenza virus infection. The EUA authority allows the FDA, based on the evaluation of available data and other things, to authorize the use of unapproved medical products or unapproved uses of approved medical products following a determination and declaration of emergency. The Focus Diagnostics test is an unapproved device whose use is authorized by the EUA. The authorization ends when the declaration of emergency is terminated or when the FDA revokes the authorization. Emergency Use Authorization is part of Project BioShield, which became law in July 2004. Focus Diagnostics is based in Cypress, Calif. For more information: FDA"s Guidance on Emergency Use Authorization of Medical Products.. U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009